Combined surgery and radiotherapy for synchronous multiple primary lung cancers: a clinical retrospective study

Author:

Kawagishi Sachi1,Kanzaki Ryu1,Watari Hirokazu1,Omura Akiisa1,Tanaka Ryo1,Maniwa Tomohiro1,Tanaka Kazunori1,Ikawa Toshiki1,Kanayama Naoyuki1,Morimoto Masahiro1,Konishi Koji1,Okami Jiro1

Affiliation:

1. Osaka International Cancer Institute

Abstract

Abstract Background The recommended treatment strategy for early-stage synchronous multiple primary lung cancers (sMPLC) involves multiple resections of all lesions, if possible. However, some patients with sMPLC cannot tolerate multiple surgeries due to comorbidities or deterioration in lung functions. We aimed to analyze the outcomes of the combination of surgery and radiotherapy for sMPLC. Methods The clinical data of patients who underwent treatment with a combination of surgery and radiotherapy for sMPLC at a single center were collected, and the outcomes were analyzed. Results Among 3578 patients with non-small cell lung cancer who underwent surgical resection with curative intent, 332 had sMPLC. Of these, 20 received a combination of surgery and radiotherapy for each tumor. Sixteen patients were male, and four were female. The median patient age was 74 years (range: 60–84 years). The median follow-up period after pulmonary resection was 42 months (range: 7–184 months). The median tumor size was 18.5 mm (range, 10–55 mm) in the first cancer and 11.9 mm (range, 4–29 mm) in the second. Pulmonary resection was performed in the first cancer, with lobectomy for nine patients, and segmentectomy and wedge resection were performed for seven and four patients, respectively. Radiotherapy was administered in the second cancer. Stereotactic body radiation therapy, 3-dimensional conformal radiation therapy, and particle radiotherapy were performed in ten, eight, and two patients, respectively. Six patients died, while 14 patients were alive. Four patients died from lung cancer and two died from other diseases. The 3-year overall survival rate was 72.4%, and the 3-year progression-free survival rate was 69.6%. The 3-year local control rate for the second cancer was 95.0%. Conclusions: Treatment with a combination of surgery and radiotherapy is a viable option for sMPLC, when surgical resection cannot be performed for all lesions.

Publisher

Research Square Platform LLC

Reference32 articles.

1. Cancer statistics, 2016;Siegel RL;CA Cancer J Clin,2016

2. (2022) JLCS. The Clinical Guide Line for Lung Cancer (2022 edn). Tokyo: Kanehara.

3. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy;Warth A;Eur Respir J,2012

4. Multiple lung cancers prognosis: what about histology?;Riquet M;Ann Thorac Surg,2008

5. Clinical features and outcomes of patients with stage I multiple primary lung cancers;Shintani Y;Cancer Sci,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3